Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,075 DKK | -1.79% | +2.36% | -19.19% |
Mar. 27 | Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 04 | FDA Extends Review of Zevra's Arimoclomol by Three Months | DJ |
Sales 2022 | - | Sales 2023 | - | Capitalization | 46.96M 327M |
---|---|---|---|---|---|
Net income 2022 | 26M 181M | Net income 2023 | -26M -181M | EV / Sales 2022 | - |
Net cash position 2022 | 42.46M 295M | Net cash position 2023 | 18.21M 127M | EV / Sales 2023 | - |
P/E ratio 2022 |
1.19
x | P/E ratio 2023 |
-1.8
x | Employees | 1 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 59.56% |
1 day | -1.79% | ||
1 week | +2.36% | ||
Current month | -10.42% | ||
1 month | -10.43% | ||
3 months | -10.48% | ||
6 months | +23.54% | ||
Current year | -19.19% |
Managers | Title | Age | Since |
---|---|---|---|
Jakob Bendtsen
CEO | Chief Executive Officer | 46 | 23-05-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jakob Have
BRD | Director/Board Member | 43 | 23-05-16 |
Chairman | 53 | 23-05-16 | |
Jakob Bendtsen
CEO | Chief Executive Officer | 46 | 23-05-16 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 1,075 | -1.79% | 14 |
24-04-23 | 1,094 | +8.90% | 63 |
24-04-22 | 1,005 | -4.01% | 29 |
24-04-19 | 1,047 | -4.80% | 66 |
24-04-18 | 1,100 | +4.74% | 7 |
Delayed Quote Nasdaq Copenhagen, April 24, 2024 at 06:21 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-19.19% | 5.44M | |
-1.51% | 104B | |
+3.22% | 97.42B | |
+1.11% | 22.2B | |
-16.53% | 21.23B | |
-8.45% | 18.33B | |
-42.33% | 16.35B | |
-20.09% | 15.06B | |
+5.47% | 13.98B | |
+28.85% | 11.66B |
- Stock Market
- Equities
- ORPHA Stock